Governments Mount Opioid Lawsuit Wave at Purdue Pharma

ANDREA FOX | November 10, 2017

article image
Governments are swamping Purdue Pharma, makers of OxyContin, with opioid lawsuits alleging the company is responsible for the costs of opioid overdose.The continuing wave of opioid lawsuits coming at the makers of OxyContin, Purdue Pharma, based in Stamford, Connecticut, is growing. Recently, 28 Wisconsin counties allege that Purdue Pharma and other companies created a public nuisance misrepresenting long-term opioid safety in their marketing. The opioid lawsuit wave grew bolder in March when the city of Everett, Washington, filed a first-of-its-kind lawsuit alleging the company knew its drug OxyContin was being diverted into a black market for opioid abuse through a clinic in Los Angeles. The uptick in actions against Purdue Pharma for deceptive actions marketing OxyContin reached the Federal level recently. Prosecutors in Connecticut are now conducting a criminal investigation into the company’s OxyContin strategies and tactics. Bloomberg reported that U.S. Attorney Deirdre Daly is gathering documentation on OxyContin’s 12 hours of pain relief claims.

Spotlight

ILC Dover

ILC Dover is a world leader in the innovative design and production of engineered products employing high-performance flexible materials. Since 1947, ILC has provided engineered solutions to complex customer problems. Known for its production of space suits for NASA, the company leverages its vast materials, engineering, process, and design experience to create high performance systems for a wide range of industries, including pharmaceutical and biopharmaceutical manufacturing, infrastructure flood protection, inflatable airships, and aeronautical and deep space systems.

OTHER ARTICLES

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | April 6, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

A pharma outsourcing mission

Article | August 18, 2021

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 4, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

Spotlight

ILC Dover

ILC Dover is a world leader in the innovative design and production of engineered products employing high-performance flexible materials. Since 1947, ILC has provided engineered solutions to complex customer problems. Known for its production of space suits for NASA, the company leverages its vast materials, engineering, process, and design experience to create high performance systems for a wide range of industries, including pharmaceutical and biopharmaceutical manufacturing, infrastructure flood protection, inflatable airships, and aeronautical and deep space systems.

Events